Principal Investigator:
Jeff Yu, MD
Massachusetts General Hospital
Overview:
Oral Janus Kinase inhibitors (JAKi) are novel therapeutic options for patients with various inflammatory skin conditions, such as alopecia areata, atopic dermatitis, and psoriasis. Currently, most of the data that exists on the long-term side effects of JAKis comes from the rheumatology literature, where JAKis are used to treat highly inflammatory systemic diseases (i.e. rheumatoid arthritis). There is scant literature on the side effect profile or recommended laboratory monitoring during the use of JAKis in dermatologic conditions. Thus, the purpose of this database will be to provide pediatric dermatologists with accurate safety information and appropriate lab monitoring during the use of JAKis in the treatment of cutaneous inflammatory diseases, such as those listed above.
Status:
This project is new and needs additional sites. If you are interested in joining this study, please contact Hadley Johnson.
